PBYI - Puma Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.54 (+1.99%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close27.13
Bid27.67 x 900
Ask28.67 x 900
Day's Range27.06 - 27.72
52 Week Range17.60 - 83.15
Avg. Volume917,387
Market Cap1.055B
Beta (3Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-3.89
Earnings DateFeb 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.89
Trade prices are not sourced from all markets
  • Business Wire13 hours ago

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on February 14, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

  • 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
    Zacks2 days ago

    5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

    Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

  • Business Wire3 days ago

    Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 28, 2019 following release of its fourth quarter and full year 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Puma Biotechnology Inc.

    Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PBYI totaled $2.52 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Need To Know: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insiders Have Been Selling Shares
    Simply Wall St.10 days ago

    Need To Know: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insiders Have Been Selling Shares

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...

  • Business Wire11 days ago

    Puma Biotechnology Announces Litigation Victory with Jury’s Decision

    Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced today that the class action lawsuit, Hsu vs. Puma Biotechnology, Inc., et. al., filed in the U.S. District Court for the Central District of California against Puma and Alan H. Auerbach, Puma’s CEO and President, has concluded with a jury verdict. Plaintiffs had claimed that four statements made in connection with Defendants’ July 2014 announcement of positive top-line results from a Phase III clinical trial of its breast cancer drug, neratinib, were “false and misleading,” and led to two stock drops in 2015 when the results of the clinical trial were presented at a medical conference. Defendants were represented by Andrew Clubok, Michele Johnson, Colleen Smith, and Sarah Tomkowiak of Latham & Watkins.

  • Is Puma Biotechnology a Buy?
    Motley Fool25 days ago

    Is Puma Biotechnology a Buy?

    Wall Street wasn't patient with the pharma company in 2018. Can the company win back analysts this year?

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on Delta Air Lines, Duke Energy, Fiserv, The Chefs' Warehouse, Maxim Integrated Products, and Puma Biotechnology — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
    Zackslast month

    Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why

    Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

  • Business Wirelast month

    Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. that grants Knight the exclusive right to commercialize NERLYNX® in Canada.

  • GlobeNewswirelast month

    Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®

    Puma filed a New Drug Submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX® in Canada.

  • Athenex Completes Enrollment Target for Breast Cancer Study
    Zackslast month

    Athenex Completes Enrollment Target for Breast Cancer Study

    Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

  • Business Wirelast month

    Puma Biotechnology to Present at J. P. Morgan Healthcare Conference

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 12:00 Noon PST on Wednesday, January 9, at the 37th Annual J.

  • Benzinga2 months ago

    A Bull And Bear Review Positive Results For Puma Biotech's Late-Stage Breast Cancer Drug Trial

    Puma Biotechnology Inc (NASDAQ: PBYI ) released positive top-line results for its lead drug candidate PB272, or Nerlynx, which is being evaluated for treating HER2+ metastatic breast cancer patients who ...

  • Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
    Zacks2 months ago

    Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer

    Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...

  • MarketWatch2 months ago

    Puma Bio stock rises more than 9% on drug study

    Shares of Puma Biotechnology Inc. rose more than 9% in the extended session Monday after the company said it has reached an agreement with the Food and Drug Administration to devise further trials for one of its drug candidates designed to treat some types of metastatic breast cancer. The company said top-line results of one of the drug's trial stages showed some improvement in survival rates. "We look forward to working with the regulatory authorities in the hope of bringing another potential treatment option to patients with HER2-positive metastatic breast cancer as soon as possible," Chief Executive Alan H. Auerbach said in a statement. Puma shares ended the regular trading day down 5%.

  • Business Wire2 months ago

    Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company's lead drug candidate PB272 in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments in the setting of metastatic disease.

  • Puma Biotechnology Inc (PBYI): Hedge Fund Sentiment Unchanged
    Insider Monkey2 months ago

    Puma Biotechnology Inc (PBYI): Hedge Fund Sentiment Unchanged

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]